EBM Medical Newsletter by Xagena
Evidence-based Medicine
EBM, una branca della Medicina che si propone di facilitare le decisioni diagnostiche e terapeutiche, con risvolti anche nella gestione delle risorse economiche
–
Statin therapy is effective at reducing the risk of contrast-induced acute kidney injury with coronary angiography
Contrast-induced acute kidney injury is an adverse outcome resulting from radiocontrast medium exposure during coronary angiography and percutaneous coronary intervention. A systematic search was c …
Inoperable patients with severe aortic stenosis: transcatheter aortic valve replacement linked to better survival and functional status
The long-term outcomes of transcatheter aortic valve replacement ( TAVR ) in inoperable patients with severe aortic stenosis remain unknown. In the Placement of Aortic Transcatheter Valves ( PARTNE …
STEMI heart attack: pre-hospital versus in-hospital thrombolysis
Early thrombolysis for individuals experiencing a myocardial infarction is associated with better mortality and morbidity outcomes. While traditionally thrombolysis is given in hospital, pre-hospital …
Cardiac resynchronisation therapy for the treatment of heart failure and ICD for the treatment of arrhythmias: assessment of clinical effectiveness and cost-effectiveness
This assessment updates and expands on two previous technology assessments that evaluated implantable cardioverter defibrillators ( ICDs ) for arrhythmias and cardiac resynchronisation therapy ( CRT ) …
Heart failure: LCZ696, an angiotensin-neprilysin inhibitor, superior to Enalapril in reducing the risks of death and of hospitalization
Researchers have compared the angiotensin receptor-neprilysin inhibitor LCZ696 with Enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, Enalapril impro …
Per iscriversi alla Newsletter Evidence Medicine in inglese
Coloro che sono GIA’ ISCRITTI ad altre Newsletter Xagena possono accedere al Pannello di Controllo al sito XagenaWeb.it inserendo l’indirizzo e-mail con il quale ricevono le Newsletter e la Password personale [ RIPORTATA IN FONDO A OGNI NEWSLETTER ] E’ importante confermare la modifica cliccando sul tasto SALVA MODIFICA